Stimulant supply instability
U.S. stimulant shortages haven’t fully cleared — brand-name Adderall and Vyvanse were recently removed from the FDA shortage list but many generic forms remain scarce, leaving continuity of care uncertain. Commentators say the instability is widening challenges for adult ADHD treatment and fueling family confusion about what to expect from medication access. (ajmc.com) (psychiatrictimes.com)
A stimulant is the kind of medicine that speeds up certain brain signals, the way turning up the volume makes one instrument easier to hear in a noisy room. For many people with attention-deficit/hyperactivity disorder, medicines like amphetamine mixed salts and lisdexamfetamine make focus, task-switching, and impulse control more manageable on an ordinary workday. (cdc.gov) The problem in April 2026 is not that every stimulant is gone. The problem is that the United States Food and Drug Administration may show one version as resolved while pharmacists still see many generic versions on shortage or allocation, which means supply is rationed and refills can fail from one month to the next. (fda.gov) (ashp.org 1) (ashp.org 2) That is why patients hear two different stories at once. Brand-name Adderall and Vyvanse can come off the federal shortage list while generic amphetamine mixed salts immediate-release tablets and generic lisdexamfetamine capsules still show broad supply trouble across multiple manufacturers. (fda.gov) (ashp.org 1) (ashp.org 2) The American Society of Health-System Pharmacists update from March 27, 2026 says generic amphetamine mixed salts immediate-release tablets remain short because of active ingredient delays. The same page says Mylan and Zydus discontinued some products, which turns a temporary squeeze into a smaller long-term supply base. (ashp.org) The lisdexamfetamine picture is similar. The American Society of Health-System Pharmacists update from April 2, 2026 says one Mallinckrodt 10 milligram capsule was on back order with an estimated May 2026 release, while many other capsule products were in limited supply and on allocation. (ashp.org) “On allocation” is pharmacy language for a controlled drip instead of a normal shelf. A store can order the drug, but the wholesaler may release only part of what the store wants, which is why one pharmacy says “in stock” and the next says “try again next week.” (ashp.org) This hits continuity of care harder than a one-time delay. Attention-deficit/hyperactivity disorder medicines are usually prescribed by exact dose and release type, so a missing 20 milligram immediate-release tablet is not automatically replaceable with a 20 milligram extended-release capsule any more than a gallon jug replaces a coffee thermos just because both hold liquid. (cdc.gov) (ashp.org 1) (ashp.org 2) The shortage is landing on a large adult patient population. A Centers for Disease Control and Prevention report published in October 2024 found that 6.0% of United States adults reported a current attention-deficit/hyperactivity disorder diagnosis, and about one half said they were diagnosed at age 18 or older. (cdc.gov) That same report found that about one third of adults with attention-deficit/hyperactivity disorder used a stimulant in the previous year. Among those stimulant users, 71.5% said they had difficulty getting a prescription filled because the medication was unavailable. (cdc.gov) Federal officials have tried to address one bottleneck by raising manufacturing quotas for attention-deficit disorder medicines, but quotas are only one valve in a longer pipeline. The Drug Enforcement Administration says production quotas were increased, while the Food and Drug Administration says shortages can also come from manufacturing problems, production delays, and discontinuations. (deadiversion.usdoj.gov) (fda.gov) The care system around these drugs is still in motion too. On December 31, 2025, the Drug Enforcement Administration and the Department of Health and Human Services extended COVID-era telemedicine prescribing flexibilities for controlled medications through December 31, 2026, so demand can still move through remote visits even while pharmacy supply remains uneven. (dea.gov) So the real story is not “shortage over” or “shortage unchanged.” It is a patchwork market where the federal list, the wholesaler’s allotment, the pharmacist’s shelf, and the patient’s exact dose can all say something different on the same day. (fda.gov) (ashp.org) (ashp.org)
